Review of eight restricted-access programs and potential implications for pharmacy

American Journal of Health-System Pharmacy

Volumn 64, Issue 12, 2007, Pages 1302-1310

  Evans, Jeffery D ^a,b   Evans, Emily W ^a  

^a UNIVERSITY OF LOUISIANA   (United States)

^b University of Louisiana Monroe College of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BOSENTAN; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLOZAPINE; DOFETILIDE; ISOTRETINOIN; OXYBATE SODIUM; SUBUXONE; THALIDOMIDE; UNCLASSIFIED DRUG; DRUG;

AGRANULOCYTOSIS; AMNESIA; COMA; CONSTIPATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG INDICATION; DRUG LABELING; DRUG MONITORING; DRUG SAFETY; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEART ATRIUM FIBRILLATION; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; NARCOLEPSY; NOTE; PATIENT SAFETY; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROTECTION; PULMONARY HYPERTENSION; QT PROLONGATION; RESTRICTED ACCESS PROGRAM; SIDE EFFECT; SKIN DISEASE; TERATOGENICITY; TORSADE DES POINTES; UNCONSCIOUSNESS; UNITED STATES; LEGAL ASPECT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; REVIEW;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PHARMACY; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34547646667     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060149     Document Type: Note

References (52)

1. Gabay MP, Costianis R. Restricted drug distribution programs. Am J Health-Syst Pharm. 2003; 60:1525-30.
2. The risk revolution: challenges and opportunities for pharmacists. J Am Pharm Assoc. 2001; 41(6 suppl 1):S18-23.
3. Food and Drug Administration. Subutex and Suboxone approved to treat opiate dependence. www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.html (accessed 2006 May 15).
4. Coffin PO, Blaney S, Fuller C et al. Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. Am J Drug Alcohol Abuse. 2006; 32:1-6.
5. Koch AI, Arfken CL, Schuster CR. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006; 83:274-8.
6. Raisch DW, Fudala PJ, Saxon AJ et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005; 45:23-32.
7. Food and Drug Administration. Information for pharmacists about Suboxone and Subutex. www.fda.gov/cder/foi/label/2002/20732pharmacist.pdf (accessed 2006 May 15).
8. Food and Drug Administration. FDA approves Xyrem for cataplexy attacks in patients with narcolepsy. www.fda.gov/bbs/topics/ANSWERS/2002/ANS01157.html (accessed 2005 Nov 8).
9. Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology, and management. CNS Drugs. 2006; 20:43-50.
10. Fuller DE, Hornfeldt CS, Kelloway JS et al. The Xyrem risk management program. Drug Saf. 2004; 27:293-306.
11. National Drug Intelligence Center. National drug threat assessment 2005. www.usdoj.gov/ndic/pubs11/12620/12620p.pdf (accessed 2005 Nov 8).
12. Snead OC III, Gibson KM. Gammahydroxybutyric acid. N Engl J Med. 2005; 352:2721-32. [Erratum, N Engl J Med. 2006; 354:537.]
13. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000; 60:273-92.
14. Zeldis JB, Williams BA, Thomas SD et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999; 21:319-30.
15. Lary JM, Daniel KL, Erickson JD et al. The return of thalidomide: can birth defects be prevented? Drug Saf. 1999; 21:161-9.
16. Nasca MR, Micali G, Cheigh NH et al. Dermatologic and nondermatologic uses of thalidomide. Ann Pharmacother. 2003; 37:1307-20.
17. Mujagic H, Chabner BA, Mujagic Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002; 43:274-85.
18. Teo SK, Harden JL, Burke AB et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 2001; 29:1355-7.
19. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995; 333:101-6.
20. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program. Arch Dermatol. 2005; 141:563-9.
21. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2005; 24:92-102.
22. Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin. 2005; 23:665-74.
23. Honein MA, Moore CA, Erickson JD. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example. Drug Saf. 2004; 27:1069-80.
24. Food and Drug Administration. FDA letter approving and outlining the iPledge program. www.fda.gov/cder/foi/appletter/2005/018662s056ltr.pdf (accessed 2006 Jan 15).
25. iPledge. Homepage of iPledge. www.ipledgeprogram.com/Default.aspx (accessed 2006 Jan 15).
26. Hoeper MM. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs. 2005; 65:1337-54.
27. Segal ES, Valette C, Oster L et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf. 2005; 28:971-80.
28. Tracleer prescribing information. www.tracleer.com/pdf/ Tracleer_PI_080706.pdf (accessed 2007 Feb 21).
29. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ. 2002; 325:592-5.
30. Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004; 27:283-92.
31. Woodstock J. Commentary: the reintroduction of Lotronex for diarrhea-predominant irritable bowel syndrome. BMJ. 2003; 327:163-4.
32. Palmer JB. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds. BMJ. 2003; 326:51. Letter.
33. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet. 2001; 357:1544-5.
34. Galson S, Kweder S, Houn F et al. The FDA and the Lancet: an exchange. Lancet. 2001; 358:415. Letter.
35. Food and Drug Administration. Patient-physician agreement for Lotronex. www.fda.gov/cder/drug/infopage/lotronex/pt_physicianAgreement200502.pdf (accessed 2006 Jan 22).
36. Alvir JM, Lieberman JA, Safferman AZ et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329:162-7.
37. Oyesanmi O, Kunkel EJ, Monti DA et al. Hematologic side effects of psychotropics. Psychosomatics. 1999; 40:414-21.
38. Williams DP, Pirmohamed M, Naisbitt DJ et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther. 1997; 283:1375-82.
39. Atkin K, Kendall F, Gould D et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996; 169:483-6.
40. Sedky K, Shaughnessy R, Hughes T et al. Clozapine-induced agranulocytosis after 11 years of treatment. Am J Psychiatry. 2005; 162:814. Letter.
41. Food and Drug Administration. Important drug warning and new information about Clozaril. www.fda.gov/medwatch/safety2006Clozaril_chart_letter_final12- 2005.pdf (accessed 2006 Jan 23).
42. Boriani G, Diemberger I, Biffi M et al. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs. 2004; 64:2741-62.
43. Food and Drug Administration. Drug approvable letter for Tikosyn. www.fda.gov/cder/foi/appletter/1999/20931ltr.pdf (accessed 2006 Feb 20).
44. Pfizer. Tikosyn (dofetilide) prescribing information. www.pfizer.com/pfizer/download/uspi_tikosyn.pdf (accessed 2006 Feb 20).
45. Pfizer. Tikosyn (dofetilide) homepage. www.tikosyn.com/ (accessed 2006 Feb 20).
46. Pfizer. Tikosyn FAQs for pharmacists. www.tikosyn.com/tikosyn_faq.asp (accessed 2006 Feb 20).
47. Uhl K, Cox E, Rogan R et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf. 2006; 29:321-9.
48. Lasser KE, Seder DL, Yu DT et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med. 2006; 166:338-44.
49. Kracov DA. Legal issues and impact of restricted access and distribution. J Am Pharm Assoc. 2001; 41(6 suppl 1):S11-5.
50. The risk revolution: challenges and opportunities for pharmacists. J Am Pharm Assoc. 2001; 41(6 suppl 1):S18-23.
51. Becker ML, Kallewaard M, Caspers PW et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf. 2005; 28:371-8.
52. Food and Drug Administration. Natalizumab (marketed as Tysabri) information. www.fda.gov/cder/drug/infopage/natalizumab/default.htm (accessed 2006 Jun 10).